Market capitalization | $369.07m |
Enterprise Value | $21.27m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.49 |
P/S ratio (TTM) P/S ratio | 8.53 |
P/B ratio (TTM) P/B ratio | 1.09 |
Revenue growth (TTM) Revenue growth | -5.97% |
Revenue (TTM) Revenue | $43.27m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 43 43 |
6%
6%
|
|
Gross Profit | 40 40 |
4%
4%
|
|
EBITDA | -144 -144 |
93%
93%
|
EBIT (Operating Income) EBIT | -146 -146 |
94%
94%
|
Net Profit | -131 -131 |
85%
85%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Jay Duker |
Employees | 165 |
Founded | 1987 |
Website | www.eyepointpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.